Tigecycline for treating bloodstream infections: a critical analysis of the available evidence

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 3, 2008, Pages 358-359

  Curcio, Daniel ^a  

^a Sanatorio San José Infectología Institucional SRL ^*  (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; DAPTOMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; METALLO BETA LACTAMASE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOOD FLOW; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTEROCOCCUS FAECIUM; KLEBSIELLA PNEUMONIAE; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OFF LABEL DRUG USE; PRIORITY JOURNAL; THROMBOPHLEBITIS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; HUMANS; MINOCYCLINE;

EID: 45549098718     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.025     Document Type: Letter

References (11)

1. Aslam S., Trautner B.W., Ramanathan V., and Darouiche R.O. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob. Agents Chemother. 51 (2007) 1556-1558
2. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E., Tigecycline 301 Study Group, and Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41 (2005) S354-S367
3. Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., and Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56 (2005) 128-132
4. Cobo J., Morosini M.I., Pintado V., Tato M., Samaranch N., Baquero F., and Cantón R. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 60 (2008) 319-322
5. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E., Tigecycline 300 cSSSI Group, and Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41 Suppl 5 (2005) S341-S353
6. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., Dowzicky M.J., and Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 215-227
7. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J. Hosp. Med. 2 (2007) 343-344
8. Lefort A., Lafaurie M., Massias L., Petegnief Y., Saleh-Mghir A., Muller-Serieys C., Le Guludec D., and Fantin B. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47 (2003) 216-222
9. Murphy T.M., Deitz J.M., Petersen P.J., Mikels S.M., and Weiss W.J. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44 (2000) 3022-3027
10. Pliatsika V., Afkou Z., Protonotariou E., and Sofianou D. In vitro activity of tigecycline against metallo-β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 60 (2007) 1406-1407
11. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., and Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58 (2006) 1221-1229